CASE REPORT

Inflammatory myofibroblastic tumor – case report

 Tumoră miofibroblastică inflamatorie – prezentare de caz

First published: 18 octombrie 2024

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/OnHe.68.3.2024.10159

Abstract

Inflammatory myofibroblastic tumors belong to the ca­te­gory of rare pathologies, predominantly affecting children and young adults. It is believed that anaplastic lymphoma kinase (ALK) mutations are the origin of these tumors. The diagnostic process is complex and difficult because of the non­spe­cific clinical and paraclinical appearances, and it is de­fined by biopsy and immunohistochemical examination. In this case report, we highlight the evolution of a 45-year-old patient, diagnosed with a uterine inflammatory myo­fi­bro­blas­tic tumor, invasive at the level of the sigmoid co­lon, difficult to completely remove it surgically. After con­fir­ming the etiology, a corticotherapeutic protocol was initiated, which led to the complete remission of the symp­toms and the reduction in size of the tumor. Periodic follow-up con­sis­ting of colonoscopy and contrast MRI con­firmed the curability of this pathology, with no adverse reac­tions of any kind reported following the treatment, pa­ving the way to even more personalized therapies, such as ALK inhibitors.
 

Keywords
myofibroblast, inflammatory, young, ALK mutations, immunohistochemical, corticotherapeutic, nonspecific

Rezumat

Tumorile miofibroblastice inflamatorii se înscriu în categoria patologiilor rare, cu afectarea predominantă a copiilor şi adulţilor tineri. Se consideră că în apariţia acestor tumori sunt implicate mutaţiile kinazei limfomului anaplazic (anaplastic lymphoma kinase; ALK). Procesul de diagnosticare este com­plex şi dificil, prin apariţia unor tablouri clinice şi para­cli­nice nespecifice, definitivate prin biopsiere şi examinare imu­no­his­to­chi­mi­că. În această prezentare de caz, descriem evo­lu­ţia unei paciente în vârstă de 45 de ani, diagnosticată cu o tumoră miofibroblastică inflamatorie uterină, invazivă la nivelul colonului sigmoid, dificil de excizat chirurgical în to­ta­li­ta­te. În urma stabilirii certe a etiologiei, s-a iniţiat un pro­to­col corticoterapeutic, în urma căruia pacienta a obţinut re­mi­siu­nea completă a simptomatologiei şi reducerea în dimensiuni a formaţiunii. Urmărirea periodică prin co­lo­no­sco­pie şi IRM cu substanţă de contrast a confirmat cu­ra­bi­litatea acestei patologii, fără a fi raportate reacţii adverse de orice fel în urma tratamentului, deschizând însă calea unor terapii şi mai personalizate, precum inhibitorii ALK.
 

Introduction

Inflammatory myofibroblastic tumors (IMTs) – also called inflammatory fibrosarcomas – represent an extremely rare pathological entity, with a prevalence of 1 case per one million inhabitants, which predominantly affects children and young adults, but not only them(1,2).

Myofibroblasts are found in the structure of these tumors, cells with a predominant structural and regenerative role after acute or chronic injuries. Therefore, these tumors develop in places where this cell type predominates, namely the surfaces of the mucous membranes and at the level of the mesentery. Due to the fact that IMT contain, in addition to myofibroblasts, also multiple cells involved in inflammatory processes (lymphocytes, eosinophils, plasma cells), they take on the appearance of inflamed/infected tissue, which can lead to confusion with a malignant tumor or infection.

The main starting point of inflammatory fibrosarcoma is the lungs but, to a lesser extent, also the larynx, stomach, liver, intestine, bladder and uterus(3). Symptoms can vary depending on the size and location of the tumor, generally structuring a rather nonspecific clinical picture: altered general condition, fever, night sweats, pain at the site of the tumor, and weight loss(4-6).

The characteristic of this pathology is mostly benign, rarely having the possibility of spreading, but with increased chances of invasion in neighboring organs. Regarding the etiopathogenesis of these tumors, studies have shown that the anaplastic lymphoma kinase (ALK) genes are involved, whose mutations induce the aberrant growth of the mentioned cell species, after an injury or even in its absence. Although it has been shown that ALK mutations can lead to myofibroblastic tumors, the genetic transmission is not clinically proven(6,7).

In order to accurately establish a diagnosis, both clinical evaluation (nonspecific symptoms in most cases), imaging investigations, anatomopathological examinations and IHC tests are involved. Among the imaging investigations, we mention ultrasound – it shows nonspecific hypo-/hyperechoic images, therefore in most cases CT or MRI is chosen, the diagnosis of certainty being established by anatomopathological examen following a biopsy(8).

From the treatment perspective, there are multiple possibilities of which the highest demonstrated efficacy was by complete surgical excision of the tumor, difficult to achieve because of the hardness and particularly adherent tumor structure(9). In the absence of a complete excision, the risk of local recurrence persists, in which case patients can receive corticosteroid therapy and new generation therapies like ALK inhibitors which have also proven their effectiveness(10-12).

Case report

A 45-year-old female patient, Caucasian, with no significant family history, with a personal history of two births and six abortions on request, presented with symptoms that had appeared approximately six months ago, consisting of intense pelvic pain, intestinal transit disorders, pain during defecation, and the presence of a palpable pseudotumoral formation in the left iliac fossa. Nine months ago, the patient requested a gynecological consultation, during which she performed a transvaginal ultrasound that identified the presence of a hypo-/hyperechoic pelvic mass. The intrauterine device was extracted, and the patient was scheduled for a pelvic MRI, Pap test and uterine biopsy curettage. The results of the two tests suggested the absence of elements of malignancy in the case of curettage and inflammatory lesions, and NILM (negative for intraepithelial lesion or malignancy) in the case of the PAP exam.

The patient underwent an MRI examination two months before the current hospitalization, revealing the appearance of a left tubo-ovarian abscess, with a fistulous path with the left lateral sigmoid wall, bilateral ovarian cysts (a large one on the left – Figure 1), hydrosalpinx on the right side, thickening of the sigmoid wall with an inflammatory appearance all over the length, intramural leiomyoma, and multiple pelvic ganglia (Figure 2).
 

Figure 1 & Figure 2
Figure 1 & Figure 2

The clinical examination revealed a supple abdomen, mobile with breathing, spontaneously and palpatory painful in the lower quadrant, where a hard tumoral formation of approximately 10 cm was found, the vaginal examination suggesting a normal-looking cervix, pain at the level of the lateral pouches, where a solid, unmovable formation was palpated. The results of the biological tests led to the diagnosis of moderate anemia (HGB values of 9.6 g/dl). ANCA antibodies, C3 and C4 complements, and electrophoresis of blood proteins recorded normal values, with fibrinogen only being increased to values of 410.5 mg/dl.

Given the clinical examination and the paraclinical tests, it was decided to perform the surgical intervention, under general anesthesia through orotracheal intubation, finding the presence of a tumoral or inflammatory block (not possible to differentiate) that included the uterus, ovaries (enlarged, with hydrosalpinx appearance) and sigmoid colon, left ovarian cyst of approximately 10 cm. Bilateral adnexectomy was performed, later the dissection of the tumor was attempted, with the release of the uterus and the sigmoid colon (difficult dissection, tissues of increased consistency). A biopsy was taken from this tissue, and the histopathological examination described a chronic inflammatory aspect, negative for malignancy, with the recommendation of an IHC test. The latter established the final diagnosis of inflammatory myofibroblastic tumor.

Postoperatively, prophylactic antibiotic treatment (meropenem + vancomycin), anti-inflammatory and symptomatic treatment was initiated, under which the evolution was favorable, with symptoms slowly alleviating.

The patient was discharged with the recommendations to avoid intense physical exertion and to return in 30 days in order to perform the colonoscopy and the control MRI examination.

After one month, the patient was hospitalized for surgical reevaluation. A colonoscopy was performed, which objectivized a normal appearance up to the level of the splenic angle, and a pelvic MRI revealed the absence of cystic images corresponding to the two ovaries that were excised, persistent slight dimensional progression of the compartmentalized cystic image located parauterine posterolaterally on the left, and obturator adenomegalia.

After the oncological examination, it was established that the patient had no indication for chemotherapy or radiotherapy, and it was decided to initiate corticosteroid therapy – initially pulse therapy with 250 mg of Solu-Medrol® for three days, then prednison 30 mg/day for one month. The reevaluation recommendation was issued after this interval.

One month later, the patient showed complete remission of symptoms and a significant reduction in the size of the tumor. The patient did not report any adverse event during the cortisone treatment.

Discussion

This case report highlights an extremely rare pathology, scarcely described in the literature. The patient hospitalized in our clinic underwent a series of imaging and laboratory investigations (colonoscopy, MRI, uterine biopsy curettage, Babeş-Papanicolaou test, IHC tests, ANCA, C3, C4, blood protein electrophoresis) until the diagnosis was confirmed.

Regarding age groups, we can confirm that the patient is part of the typical category of appearance of this pathology, the symptoms starting at the age of 45, confirming the hypotheses released from published studies(1,2).

It is also interesting to analyze the evolution of the patient’s general condition under the chosen therapeutic protocol, and the fact that she entered complete remission and the prognosis is favorable, approximately four years after the intervention and the completion of the corticosteroid protocol. The lack of local recurrence can highlight the importance of the complementarity between complete surgical excision and the individualized corticotherapeutic regime(9-12).

The location of the original tumor could not be determined, but it was most likely originated from the aberrant myofibroblastic proliferation at the level of the uterine mucosa, with a subsequent inclusion in a massive inflammatory process of the adjacent organs (sigmoid colon, ovaries). We highlight that the lungs remain the preferred location of inflammatory fibrosarcomas, but this particular case reinforces the idea of ​​not excluding other sites of tumor origin(3). It is imperative to mention the fact that ultrasound cannot provide sufficient information about IMTs with findings like hypo- and hyperechogenicity, MRI and CT becoming the investigations of choice in cases where a myofibroblastic tumor is suspected(8).

Another important aspect is the differential diagnosis, namely the fact that myofibroblasts, the main cell type in the IMTs, are cells of mesenchymal origin, having common ultrastructural characteristics with fibroblasts and smooth muscle cells(8). Myofibroblastic differentiation is observed both in benign tumors such as nodular fasciitis, as well as in intermediate malignant tumors such as desmoid fibromatosis. The specialized literature highlights as a unique purely malignant process of mesenchymal origin, which includes myofibroblastic proliferation and low-grade myofibroblastic sarcoma. In the differentiation process of these conditions, a huge role is held by the IHC exam.

Conclusions

We are facing an extremely rare pathology, and this prevalence is probably determined by its underdiagnosis. The technological progress and, therefore, the diagnostic possibilities can represent a real starting point for increasing the discovery rates of the less frequent pathologies.

In the birth process of inflammatory myofibroblastic tumors, the genetic mutation at the level of the ALK gene was confirmed as a possible cause, representing the chance of developing targeted and super-specialized therapies, based on specific inhibitors of this gene, such as crizotinib, cirotinib, alectinib, brigatinib and lorlatinib.

The publication rate of these cases of rare pathology remains crucial in order to form a useful database for the development of specialized diagnostic and treatment protocols. It is mandatory that the questions that have not been answered at the present moment represent the encouragement for organizing clinical studies and, at the same time, for laboratories to confirm the tumoral genomic profile, accepting the idea that in modern pathology, very often, genetic mutations represent a promoter of the pathology.

Starting from these principles, we can look for modern perspectives of diagnosis, staging and treatment, even in the case of extremely rare pathologies in the category of which the inflammatory myofibroblastic tumor is part of. 

 

 

Autori pentru corespondenţă: Cristina-Raluca Iorga E-mail: cristina.iorga@umfcd.ro

CONFLICT OF INTEREST: none declared.

FINANCIAL SUPPORT: none declared.

This work is permanently accessible online free of charge and published under the CC-BY.

A grey and black sign with a person in a circle

Description automatically generated

Bibliografie

  1. Surabhi VR, Chua S, Patel RP, Takahashi N, Lalwani N, Prasad SR. Inflammatory Myofibroblastic Tumors: Current Update. Radiol Clin North Am. 2016;54(3):553-563.

  2. Panagiotopoulos N, Patrini D, Gvinianidze L, Woo WL, Borg E, Lawrence D. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm?. J Thorac Dis. 2015;7(5):908-911.

  3. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now?. 

  4. J Clin Pathol. 2008;61(4):428-437.

  5. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19(8):859-872.

  6. Choi AH, Bohn OL, Beddow TD, McHenry CR. Inflammatory myofibroblastic tumor 

  7. of the small bowel mesentery: an unusual cause of abdominal pain and uveitis. 

  8. J Gastrointest Surg. 2011;15(4):584-588.

  9. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19(8):859-872.

  10. Chan JK, Cheuk W, Shimizu M. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol. 2001;25(6):761-768.

  11. Elpek GÖ. Inflammatory Myofibroblastic Tumor of the Liver: A Diagnostic Challenge. J Clin Transl Hepatol. 2014;2(1):53-57.

  12. Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365. 

  13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer [published correction appears in N Engl J Med. 2011 Feb 10;364(6):588]. N Engl J Med. 2010;363(18):1693-1703.

  14. Butrynski JE, D’Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727-1733.

  15. Zhu Z, Zha Y, Wang W, Wang X, Gao Y, Lv W. Inflammatory Myofibroblastic Tumors in Paranasal Sinus and Nasopharynx: A Clinical Retrospective Study of 13 Cases. Biomed Res Int. 2018;2018:7928241.

Articole din ediţiile anterioare

AFECȚIUNILE MALIGNE LA TINERI | Ediţia 2 / 2015

Youth Cancer Europe Open Space Summit. Key Outcomes Report

The focus of the Open Space Summit was to assess the most urgent unmet needs that young people across Europe have identified and to enable an open ...

24 aprilie 2015
PREZENTARE DE CAZ | Ediţia 2 / 2015

Tumora Wilms la adultul tânăr

Conf. dr. Dana Lucia Stănculeanu, Daniela Zob, Bogdan Georgescu, Raluca Bunghez

Tumora Wilms sau nefroblastomul este cea mai frecventă tumoră renală la copii, doar 3% din toate cazuri sunt întâlnite la tinerii adulţi. Principal...

24 aprilie 2015
LETTER TO THE EDITOR | Ediţia 1 54 / 2021

Patologie rară cu debut atipic şi abordare multidisciplinară

Tribus Laura Carina, Prof. Dr. Carmen Georgeta Fierbinţeanu-Braticevici, Andreea Marin, Ovidiu Calapod, Ana Maria Vlădăreanu, Prof. Dr. Horia Bumbea, Iuliana Iordan, Minodora Onisâi

Limfohistiocitoza hemofagocitară (HLH) este un sindrom rar, ameninţător de viaţă, cauzat de o inflamaţie necontrolată şi de distrucţia ţesuturilor....

24 martie 2021
CASE PRESENTATION | Ediţia 2 59 / 2022

Refractory immune thrombocytopenia – case presentation

Iuliana Iordan, Andreea Neculcea, Stejara Nicoleta Mihai, Diana Emanuela Bonea, Andreea Spînu, Alina Mititelu, Claudiu Popescu, Raluca Truican, Anca Nicolescu, Ana Maria Vlădăreanu

Trombocitopenia imună este o boală autoimună care implică distrugerea trombocitelor în splină. Adesea, pacienţii nu răspund la terapia convenţional...

31 mai 2022